We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Collagen Solutions Plc | LSE:COS | London | Ordinary Share | GB00B94T6Y14 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 6.625 | 6.25 | 7.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMCOS
RNS Number : 5735Z
Collagen Solutions PLC
18 December 2017
December 18, 2017
Collagen Solutions Plc
(the "Company" or the "Group")
Collagen Solutions Strengthens Board with Non-Executive Appointment
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen and tissue components for use in regenerative medicine applications including orthopaedics, dental, wounds, and cardiovascular is pleased to announce the appointment of Chris Brinsmead CBE to the Non-Executive Board.
Chris Brinsmead (58) has worked in the Pharmaceutical industry for over thirty years, holding executive leadership roles within ICI and AstraZeneca. He was President of the ABPI from 2008 to 2010. He is currently on the Board of UDG Healthcare plc and The Wesleyan Assurance Society, having previously held Board positions at Domino Printing Sciences plc, Cambian Group plc and Kinapse Ltd. He also chairs two private companies, Proveca Ltd and Bamburgh Capital Ltd. Chris is a Member of Council at Imperial College and an advisor and champion on Life Sciences for the UK Government. He was appointed a CBE in January 2015.
Chris Brinsmead holds a BSc in Civil Engineering from Nottingham University and an MSc in Business Science from Manchester Business School.
Commenting on this appointment, Jamal Rushdy, CEO of Collagen Solutions said: "We are delighted to have Chris join Collagen Solutions' Board at this pivotal time as we look to significantly expand our core business and launch exciting new proprietary products. His extensive and diverse executive and non-executive experience within the global life sciences arena, including leadership roles in the successful launch of commercial products, will strengthen our strategy and focus on execution for growth."
Current Directorships Previous Directorships -------------------------- -------------------------- UDG Healthcare plc Cambian Group Plc The Wesleyan Assurance Kinapse Limited Society Domino Printing Sciences Proveca Limited Plc Bamburgh Capital Limited Datapharm Communications Limited CDB (Meadowside) Limited -------------------------- --------------------------
Chris Brinsmead holds 1,731,250 ordinary shares in the capital of the Company.
About Collagen Solutions:
Collagen Solutions Plc is a global provider of medical grade collagen formulations and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The capabilities of the Company include the provision of native, soluble and powdered collagen formulations, processed and semi-processed tissues such as pericardium, bone, and blood vessels, and expertise in the development and contract manufacture of collagen components for use as engineered tissue scaffolds and other medical devices. These products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology. Collagen Solutions' unique offering extends beyond material supply and contract services through the highly skilled staff who support customers through the various stages of development and regulatory approval. For additional information, please visit www.collagensolutions.com.
Enquiries:
Hot Features
Premium
Collagen Solutions Plc
Jamal Rushdy, Chief Executive Via Walbrook
Officer
Gill Black, Chief Financial
Officer Tel: 07721 413 496 or lisa.baderoon@collagensolutions.com
Lisa Baderoon, Head
of Investor Relations
Cenkos Securities plc (Nominated Tel: 0207 397 8900
Adviser and Broker)
Stephen Keys
Steve Cox
Walbrook PR Tel: 020 7933 8780 or
collagen@walbrookpr.com
Mike Wort Mob: 07900 608 002
Anna Dunphy Mob: 07876 741 001
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOALLFFDFVLRLID
(END) Dow Jones Newswires
December 18, 2017 02:00 ET (07:00 GMT)
1 Year Collagen Solutions Chart |
1 Month Collagen Solutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
